JNJ · Johnson & Johnson - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.06B | - | $23.99B | $23.74B | $21.89B | - | $22.47B | $22.45B | $21.38B | - |
| Cost of Revenue | $8.11B | - | $7.30B | $7.63B | $7.36B | - | $6.96B | $6.87B | $6.51B | - |
| Gross Profit | $15.96B | - | $16.69B | $16.11B | $14.54B | - | $15.51B | $15.58B | $14.87B | - |
| R&D | $3.53B | - | $3.67B | $3.52B | $3.23B | - | $4.95B | $3.44B | $3.54B | - |
| SG&A | $6.03B | - | $5.92B | $5.89B | $5.11B | - | $5.48B | $5.68B | $5.26B | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $2.00B | - | - | - | $1.77B | - | - | - | $1.81B | - |
| Operating Income | $5.99B | - | $7.49B | $6.49B | $13.63B | - | $3.34B | $5.75B | $3.71B | - |
| Interest Expense | $272.00M | - | $245.00M | $308.00M | $155.00M | - | $193.00M | $270.00M | $155.00M | - |
| Income Tax | $755.00M | - | $2.34B | $954.00M | $2.63B | - | $644.00M | $1.06B | $459.00M | - |
| Net Income | $5.24B | - | $5.15B | $5.54B | $11.00B | - | $2.69B | $4.69B | $3.25B | - |
| EPS - Basic | $2.17 | - | $2.14 | $2.30 | $4.57 | - | $1.12 | $1.95 | $1.35 | - |
| EPS - Diluted | $2.14 | - | $2.12 | $2.29 | $4.54 | - | $1.11 | $1.93 | $1.34 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.69B | $19.71B | $18.23B | $18.58B | $38.47B | $24.11B | $19.98B | $24.88B | $25.47B | $21.86B |
| Accounts Receivable | $17.72B | $17.18B | $17.61B | $17.85B | $16.02B | $14.84B | $16.17B | $15.79B | $14.95B | $14.87B |
| Inventory | $14.58B | $14.19B | $14.15B | $13.41B | $12.66B | $12.44B | $12.60B | $12.17B | $11.38B | $11.18B |
| Accounts Payable | $10.46B | $11.99B | $9.63B | $9.46B | $9.54B | $10.31B | $8.95B | $8.85B | $8.17B | $9.63B |
| Current Assets | $59.17B | $55.62B | $54.61B | $54.50B | $71.55B | $55.89B | $53.25B | $57.82B | $57.00B | $53.49B |
| Total Assets | $200.89B | $199.21B | $192.82B | $193.39B | $193.67B | $180.10B | $178.29B | $181.09B | $171.97B | $167.56B |
| Current Liabilities | $57.72B | $54.13B | $50.87B | $54.18B | $56.90B | $50.32B | $51.76B | $53.93B | $48.73B | $46.28B |
| Long-term Debt | $37.53B | $39.44B | $39.41B | $39.23B | $38.35B | $30.65B | $31.29B | $31.64B | $25.08B | $25.88B |
| Total Liabilities | $119.71B | $117.67B | $113.54B | $114.92B | $115.56B | $108.61B | $108.13B | $109.55B | $101.95B | $98.78B |
| Stockholders' Equity | $81.19B | $81.54B | $79.28B | $78.47B | $78.11B | $71.49B | $70.16B | $71.54B | $70.02B | $68.77B |
| Retained Earnings | $169.16B | $168.98B | $167.28B | $165.37B | $162.63B | $155.79B | $155.18B | $155.36B | $153.38B | $153.84B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.51B | - | - | - | $4.17B | - | - | - | $3.66B | - |
| Investing Cash Flow | ($1.04B) | - | - | - | ($297.00M) | - | - | - | ($464.00M) | - |
| Financing Cash Flow | $530.00M | - | - | - | $10.42B | - | - | - | $546.00M | - |
| CapEx | $1.05B | - | - | - | $795.00M | - | - | - | $807.00M | - |
| Free Cash Flow | $1.47B | - | - | - | $3.38B | - | - | - | $2.85B | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 66.3% | - | 69.6% | 67.9% | 66.4% | - | 69.0% | 69.4% | 69.6% | - |
| Operating margin | 24.9% | - | 31.2% | 27.3% | 62.3% | - | 14.9% | 25.6% | 17.4% | - |
| EBITDA margin | 33.2% | - | - | - | 70.4% | - | - | - | 25.9% | - |
| Net margin | 21.8% | - | 21.5% | 23.3% | 50.2% | - | 12.0% | 20.9% | 15.2% | - |
| Free cash flow margin | 6.1% | - | - | - | 15.4% | - | - | - | 13.3% | - |
| FCF / Net income | 0.28 | - | - | - | 0.31 | - | - | - | 0.88 | - |
| R&D / Revenue | 14.7% | - | 15.3% | 14.8% | 14.7% | - | 22.0% | 15.3% | 16.6% | - |
| SG&A / Revenue | 25.1% | - | 24.7% | 24.8% | 23.3% | - | 24.4% | 25.3% | 24.6% | - |
| Effective tax rate | 12.6% | - | 31.2% | 14.7% | 19.3% | - | 19.3% | 18.5% | 12.4% | - |
| Return on assets | 2.6% | - | 2.7% | 2.9% | 5.7% | - | 1.5% | 2.6% | 1.9% | - |
| Return on equity | 6.4% | - | 6.5% | 7.1% | 14.1% | - | 3.8% | 6.6% | 4.6% | - |
| Return on invested capital | 4.4% | - | 4.3% | 4.7% | 9.4% | - | 2.7% | 4.5% | 3.4% | - |
| Liquidity | ||||||||||
| Current ratio | 1.03 | 1.03 | 1.07 | 1.01 | 1.26 | 1.11 | 1.03 | 1.07 | 1.17 | 1.16 |
| Quick ratio | 0.77 | 0.77 | 0.80 | 0.76 | 1.03 | 0.86 | 0.79 | 0.85 | 0.94 | 0.91 |
| Cash ratio | 0.38 | 0.36 | 0.36 | 0.34 | 0.68 | 0.48 | 0.39 | 0.46 | 0.52 | 0.47 |
| Leverage | ||||||||||
| Debt / Equity | 0.46 | 0.48 | 0.50 | 0.50 | 0.49 | 0.43 | 0.45 | 0.44 | 0.36 | 0.38 |
| Debt / Assets | 0.19 | 0.20 | 0.20 | 0.20 | 0.20 | 0.17 | 0.18 | 0.17 | 0.15 | 0.15 |
| Debt / EBITDA | 4.69 | - | - | - | 2.49 | - | - | - | 4.54 | - |
| Interest coverage | 22.0x | - | 30.6x | 21.1x | 87.9x | - | 17.3x | 21.3x | 24.0x | - |
| Equity multiplier | 2.47 | 2.44 | 2.43 | 2.46 | 2.48 | 2.52 | 2.54 | 2.53 | 2.46 | 2.44 |
| Liabilities / Assets | 0.60 | 0.59 | 0.59 | 0.59 | 0.60 | 0.60 | 0.61 | 0.60 | 0.59 | 0.59 |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | - | 0.12 | 0.12 | 0.11 | - | 0.13 | 0.12 | 0.12 | - |
| Inventory turnover | 0.56 | - | 0.52 | 0.57 | 0.58 | - | 0.55 | 0.56 | 0.57 | - |
| Days sales outstanding | 269d | - | 268d | 274d | 267d | - | 263d | 257d | 255d | - |
| Days inventory outstanding | 657d | - | 707d | 642d | 628d | - | 661d | 647d | 638d | - |
| Days payable outstanding | 471d | - | 481d | 453d | 474d | - | 469d | 470d | 458d | - |
| Cash conversion cycle | 454d | - | 494d | 463d | 422d | - | 454d | 433d | 435d | - |
| Valuation | ||||||||||
| P / E | 112.4x | - | 84.8x | 66.6x | 36.1x | - | 145.4x | 75.7x | 118.1x | - |
| P / B | 7.2x | - | 5.5x | 4.7x | 5.1x | - | 5.6x | 4.9x | 5.5x | - |
| P / S | 24.4x | - | 18.2x | 15.5x | 18.1x | - | 17.4x | 15.8x | 18.0x | - |
| EV / EBITDA | 75.5x | - | - | - | 25.8x | - | - | - | 69.5x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 9.9% | - | 6.8% | 5.8% | 2.4% | - | 5.2% | -12.1% | -13.6% | - |
| Revenue CAGR (3y) | -0.9% | - | 0.3% | -0.4% | -2.2% | - | -1.3% | -1.3% | -1.4% | - |
| Revenue CAGR (5y) | 1.5% | - | 2.6% | 5.3% | 1.1% | - | 1.6% | 1.8% | 1.3% | - |
| Gross profit growth (YoY) | 9.8% | - | 7.6% | 3.4% | -2.3% | - | 5.2% | -10.0% | -9.0% | - |
| Operating income growth (YoY) | -56.1% | - | 124.5% | 12.9% | 267.0% | - | -36.0% | -15.0% | - | - |
| Net income growth (YoY) | -52.4% | - | 91.2% | 18.2% | 237.9% | - | -89.6% | -8.9% | - | - |
| EPS growth (YoY) | -52.9% | - | 91.0% | 18.7% | 238.8% | - | -89.1% | -1.5% | - | - |
| EPS CAGR (3y) | - | - | 8.1% | 8.4% | 33.0% | - | -6.8% | -6.4% | -16.7% | - |
| EPS CAGR (5y) | -1.6% | - | 9.8% | 11.0% | 15.9% | - | 11.0% | -1.5% | -0.7% | - |
| FCF growth (YoY) | -56.6% | - | - | - | 18.6% | - | - | - | 19.0% | - |
| FCF CAGR (5y) | -15.5% | - | - | - | 4.3% | - | - | - | -0.3% | - |
| Book value growth (YoY) | 3.9% | 14.1% | 13.0% | 9.7% | 11.6% | 3.9% | -1.5% | -4.8% | -1.2% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-28.
Business segments
$34.31B totalInnovative Medicine$25.38B · 74.0%
Med Tech$8.93B · 26.0%
Product / service
$53.68B totalDARZALEX$8.27B · 15.4%
Stelara$3.85B · 7.2%
Tremfya$3.53B · 6.6%
ELECTROPHYSIOLOGY$2.89B · 5.4%
INVEGASUSTENNAXEPLIONTRINZATREVICTA$2.73B · 5.1%
Xarelto$2.63B · 4.9%
GENERAL$2.26B · 4.2%
TRAUMA$2.06B · 3.8%
ADVANCED$1.90B · 3.5%
CONTACTLENSESOTHER$1.75B · 3.3%
SPINESPORTSOTHER$1.66B · 3.1%
OPSUMIT$1.63B · 3.0%
UPTRAVI$1.54B · 2.9%
CARVYKTI$1.49B · 2.8%
SPRAVATO$1.49B · 2.8%
Erleada$1.45B · 2.7%
Abiomed$1.39B · 2.6%
PREZISTAPREZCOBIXREZOLSTASYMTUZA$1.23B · 2.3%
Simponi Simponi Aria$1.19B · 2.2%
Remicade$1.17B · 2.2%
HIPS$1.08B · 2.0%
KNEES$924.00M · 1.7%
Shockwave Medical Inc.$897.00M · 1.7%
IMBRUVICA$892.00M · 1.7%
CAPLYTA$700.00M · 1.3%
Other$542.00M · 1.0%
RYBREVANTLAZCLUZE$534.00M · 1.0%
SURGICAL$471.00M · 0.9%
TECVAYLI$444.00M · 0.8%
TALVEY$340.00M · 0.6%
Other Oncology$214.00M · 0.4%
OTHERNEUROSCIENCE$159.00M · 0.3%
Other Cardiovascular$124.00M · 0.2%
CONCERTAMethylphenidate$82.00M · 0.2%
Other Immunology$59.00M · 0.1%
Other Pulmonary Hypertension$54.00M · 0.1%
EDURANTrilpivirine$26.00M · 0.0%
ZYTIGA$23.00M · 0.0%
Other Infectious Diseases$12.00M · 0.0%
Geographic
$65.82B totalEurope$21.54B · 32.7%
Asia Pacific Africa$14.03B · 21.3%
US$13.66B · 20.8%
Non Us$11.72B · 17.8%
Western Hemisphere Excluding US$4.88B · 7.4%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing JOHNSON & JOHNSON against the 5 most active filers in the same SIC group.
Dividends
$5.24/share trailing 12 months · +4.4% YoY
| Ex-date | Per share |
|---|---|
| May 26, 2026 | $1.3400 |
| Feb 24, 2026 | $1.3000 |
| Nov 25, 2025 | $1.3000 |
| Aug 26, 2025 | $1.3000 |
| May 27, 2025 | $1.3000 |
| Feb 18, 2025 | $1.2400 |
| Nov 26, 2024 | $1.2400 |
| Aug 27, 2024 | $1.2400 |
| May 20, 2024 | $1.2400 |
| Feb 16, 2024 | $1.1900 |
| Nov 20, 2023 | $1.1900 |
| Aug 25, 2023 | $1.1900 |
| May 22, 2023 | $1.1900 |
| Feb 17, 2023 | $1.1300 |
| Nov 21, 2022 | $1.1300 |
| Aug 22, 2022 | $1.1300 |
| May 23, 2022 | $1.1300 |
| Feb 18, 2022 | $1.0600 |
| Nov 22, 2021 | $1.0600 |
| Aug 23, 2021 | $1.0600 |
| May 24, 2021 | $1.0600 |
| Feb 22, 2021 | $1.0100 |
| Nov 23, 2020 | $1.0100 |
| Aug 24, 2020 | $1.0100 |